AU2015301782B2 - Method for the treatment of depression - Google Patents

Method for the treatment of depression Download PDF

Info

Publication number
AU2015301782B2
AU2015301782B2 AU2015301782A AU2015301782A AU2015301782B2 AU 2015301782 B2 AU2015301782 B2 AU 2015301782B2 AU 2015301782 A AU2015301782 A AU 2015301782A AU 2015301782 A AU2015301782 A AU 2015301782A AU 2015301782 B2 AU2015301782 B2 AU 2015301782B2
Authority
AU
Australia
Prior art keywords
patient
depression
acid
treatment
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015301782A
Other languages
English (en)
Other versions
AU2015301782A1 (en
Inventor
Wayne C. Drevets
Qingqin S. Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2015301782A1 publication Critical patent/AU2015301782A1/en
Application granted granted Critical
Publication of AU2015301782B2 publication Critical patent/AU2015301782B2/en
Priority to AU2020281101A priority Critical patent/AU2020281101A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Otolaryngology (AREA)
AU2015301782A 2014-08-13 2015-08-12 Method for the treatment of depression Ceased AU2015301782B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020281101A AU2020281101A1 (en) 2014-08-13 2020-12-03 Method for the treatment of depression

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462036896P 2014-08-13 2014-08-13
US62/036,896 2014-08-13
PCT/US2015/044830 WO2016025581A1 (en) 2014-08-13 2015-08-12 Method for the treatment of depression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020281101A Division AU2020281101A1 (en) 2014-08-13 2020-12-03 Method for the treatment of depression

Publications (2)

Publication Number Publication Date
AU2015301782A1 AU2015301782A1 (en) 2017-03-02
AU2015301782B2 true AU2015301782B2 (en) 2020-09-03

Family

ID=55301311

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015301782A Ceased AU2015301782B2 (en) 2014-08-13 2015-08-12 Method for the treatment of depression
AU2020281101A Abandoned AU2020281101A1 (en) 2014-08-13 2020-12-03 Method for the treatment of depression

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020281101A Abandoned AU2020281101A1 (en) 2014-08-13 2020-12-03 Method for the treatment of depression

Country Status (11)

Country Link
US (1) US10098854B2 (enExample)
EP (1) EP3179993B1 (enExample)
JP (1) JP6545788B2 (enExample)
KR (1) KR20170040800A (enExample)
CN (1) CN106714789A (enExample)
AU (2) AU2015301782B2 (enExample)
CA (1) CA2957926A1 (enExample)
IL (2) IL250490A0 (enExample)
MA (1) MA40462A (enExample)
MX (1) MX2017001908A (enExample)
WO (1) WO2016025581A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
WO2015037248A1 (en) 2013-09-13 2015-03-19 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
US9610259B2 (en) * 2014-01-14 2017-04-04 Children's Hospital Medical Center Compositions and methods for treating an autism spectrum disorder
KR20170054470A (ko) 2014-09-15 2017-05-17 얀센 파마슈티카 엔.브이. VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
IL275482B1 (en) 2017-12-22 2025-03-01 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
EP3753557B1 (en) 2018-02-15 2025-11-05 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
EP3813808A4 (en) 2018-05-04 2022-01-26 Perception Neuroscience, Inc. Methods of treating substance abuse
EP3628313B1 (en) * 2018-09-28 2025-02-12 Novohale Therapeutics, LLC Ketamine composition for use in a method of treatment of depression by pulmonary administration
CN113632174B (zh) 2019-01-23 2025-03-25 密歇根大学董事会 用于nmda、甘氨酸和ampa受体的调节剂的药物基因组学决策支持
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
US20210407643A1 (en) * 2020-06-25 2021-12-30 Greenway Dna Inc. Methods and systems for providing a personalized treatment regimen using cannabinoid or psychedelic compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070287753A1 (en) * 2006-03-22 2007-12-13 Mount Sinai School Of Medicine Intranasal Administration of Ketamine to Treat Depression
DE102007009888A1 (de) * 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US20140093592A1 (en) * 2012-03-12 2014-04-03 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JPS632932A (ja) 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
DE4312016A1 (de) 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
ATE292956T1 (de) 1998-07-24 2005-04-15 Seo Hong Yoo Klare wässrige lösungen enthaltend gallensäuren
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
EP1103256A1 (de) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
MXPA05000294A (es) 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
BRPI0711872A2 (pt) 2006-05-22 2011-12-06 Vanda Pharmaceuticals Inc tratamento para distúrbios depressivos
WO2009131794A1 (en) 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US8846765B2 (en) 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination
AU2012340015B2 (en) 2011-11-14 2017-09-21 Alfasigma S.P.A. Assays for selecting a treatment regimen for a subject with depression and methods for treatment
SG11201501292UA (en) 2012-08-23 2015-05-28 Stuart L Weg Anxiolytic composition, formulation and method of use
EP2983787B1 (en) 2013-04-12 2019-10-02 Icahn School of Medicine at Mount Sinai Method for treating post-traumatic stress disorder
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070287753A1 (en) * 2006-03-22 2007-12-13 Mount Sinai School Of Medicine Intranasal Administration of Ketamine to Treat Depression
DE102007009888A1 (de) * 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US20140093592A1 (en) * 2012-03-12 2014-04-03 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KYLE A.B. LAPIDUS ET AL, "A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder", BIOLOGICAL PSYCHIATRY, (2014-04-03), vol. 76, no. 12, doi:10.1016/j.biopsych.2014.03.026, ISSN 0006-3223, pages 970 - 976 *
Tansey et al; Biol Psychiatry, vol. 73, 2013, pp. 679-682. *

Also Published As

Publication number Publication date
EP3179993A1 (en) 2017-06-21
IL279627A (en) 2021-03-01
CN106714789A (zh) 2017-05-24
US20160045455A1 (en) 2016-02-18
AU2015301782A1 (en) 2017-03-02
JP2017524719A (ja) 2017-08-31
US10098854B2 (en) 2018-10-16
JP6545788B2 (ja) 2019-07-17
KR20170040800A (ko) 2017-04-13
EP3179993B1 (en) 2021-01-20
CA2957926A1 (en) 2016-02-18
WO2016025581A1 (en) 2016-02-18
AU2020281101A1 (en) 2021-01-07
MA40462A (fr) 2017-06-21
IL250490A0 (en) 2017-03-30
EP3179993A4 (en) 2018-03-28
MX2017001908A (es) 2017-08-08

Similar Documents

Publication Publication Date Title
AU2015301782B2 (en) Method for the treatment of depression
US20230089113A1 (en) Methods For The Treatment Of Depression
US9499868B2 (en) Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate
JP6528158B2 (ja) Ｄｒｄ２又はａｎｋｋ１のｓｎｐ遺伝子型に基づく抗精神病治療
AU737893B2 (en) Diagnosis of migraine with aura, depression and anxiety from allelic variations in dopaminergic genes
Class et al. Patent application title: DETERMINATION OF SINGLE NUCLEOTIDE POLYMORPHISMS USEFUL TO PREDICT RESPONSE FOR GLATIRAMER ACETATE Inventors: Teva Pharmaceutical Industries, Ltd.(Petach-Tikva, IL) Amir Tchelet (Hod-Hasharon, IL) Fabio Macciardi (Irvine, CA, US) Joseph Levy (Kfar-Sava, IL) Assignees: Teva Pharmaceutical Industries Ltd.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired